Beta Bionics

BBNX

Market cap $1.28B

IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.

IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time): Wolfe Research 7th Annual Healthcare Conference on Tuesday, November 18, 2025 at 2:00pm Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30pm The presentations will be webcast live.

Beta Bionics, Inc. (NASDAQ:BBNX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Blake Beber - Head of Investor Relations Sean Saint - President, CEO & Director Stephen Feider - CFO, Treasurer & Secretary Conference Call Participants Michael Kratky - Leerink Partners LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Stephanie Piazzola - BofA Securities, Research Division Michael Polark - Wolfe Research, LLC Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Richard Newitter - Truist Securities, Inc., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Beta Bionics Third Quarter 2025 Earnings Conference Call.

Although the revenue and EPS for Beta Bionics, Inc. (BBNX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025.

IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025.

Beta Bionics, Inc. (NASDAQ:BBNX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Stephen Feider - CFO, Treasurer & Secretary Sean Saint - President, CEO & Director Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Stephen Feider CFO, Treasurer & Secretary I'm Stephen, and this is Sean. Patrick Wood MD of Equity Research Welcome.

Beta Bionics' iLet product is gaining traction, but management's conservative guidance has created uncertainty around future growth and competitiveness. Recent quarters showed strong revenue growth and improved guidance, but operating losses remain substantial, and operating leverage is lacking. The company's valuation has rebounded sharply, now trading at about 6 times sales, reflecting renewed optimism but also higher expectations.

IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time): Wells Fargo 20th Annual Healthcare Conference on Thursday, September 4, 2025 at 3:45pm Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:50pm Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 9:40am The presentations at the Wells Fargo and Morgan Stanley conferences will be webcast live.

Beta Bionics, Inc. (NASDAQ:BBNX ) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.